Literature DB >> 30202902

Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer.

Pei Liang1, Susanne M Henning1, Johnny Guan1, Tristan Grogan2, David Elashoff2, Jerrold M Olefsky3, Pinchas Cohen4, William J Aronson1,5.   

Abstract

Background: GPR120, a G protein-coupled receptor for long-chain polyunsaturated fatty acids (FAs), mediates the anti-inflammatory effects of omega-3 (ω-3) FAs. We investigated whether host or tumor GPR120 plays a role in the anti-prostate cancer effects of ω-3 FAs.
Methods: MycCap prostate cancer allografts were grown in immunocompetent wild-type (WT) and GPR120 knockout (KO) mice fed ω-3 (fish oil) or ω-6 (corn oil) diets. Immune cell infiltration was quantified by flow cytometry, and gene expression of immune cell markers in isolated tumor-associated macrophages (TAMs) was quantified by quantitative real-time polymerase chain reaction. Archived tissue from a fish oil intervention trial was used to correlate gene expression of GPR120 with cell cycle progression (CCP) genes and Ki67 index (n = 11-15 per group). All statistical tests were two-sided.
Results: In WT mice (n = 7 per group), dietary ω-3 FAs decreased MycCap allograft tumor growth (mean [SD] final tumor volume ω-6 = 491 [437] mm3 vs ω-3 = 127 [77] mm3, P = .04), whereas in global GPR120KO mice (n = 7 per group) ω-3 FAs had no anticancer effects. Dietary ω-3 FAs inhibited GPR120KO-MycCaP allografts grown in WT mice (n = 8 per group; mean [SD] final tumor volume ω-6 = 776 [767] mm3 vs ω-3 = 36 [34] mm3, P = .02). Omega-3 FA treatment decreased the number of M2-like TAMs in tumor tissue and gene expression of M2 markers in isolated TAMs compared with ω-6 controls in WT (n = 7 per group) but not in GPR120KO mice (n = 7 per group). In human tissue, higher expression of stromal GPR120 correlated with greater reduction in expression of CCP genes in men with prostate cancer on a high-ω-3 diet (r = -.57, P = .04). Conclusions: Host GPR120 plays a central role in the anti-prostate cancer effects of dietary ω-3 FAs. Future studies are required to determine if the anticancer effects of ω-3 FAs are mediated through inhibition of M2-like macrophages and if host GPR120 status predicts anticancer effects of dietary ω-3 FAs in men with prostate cancer.

Entities:  

Year:  2019        PMID: 30202902      PMCID: PMC6335116          DOI: 10.1093/jnci/djy125

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  33 in total

Review 1.  Effects of omega-3 fatty acids on cancer risk: a systematic review.

Authors:  Catherine H MacLean; Sydne J Newberry; Walter A Mojica; Puja Khanna; Amalia M Issa; Marika J Suttorp; Yee-Wee Lim; Shana B Traina; Lara Hilton; Rena Garland; Sally C Morton
Journal:  JAMA       Date:  2006-01-25       Impact factor: 56.272

2.  Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.

Authors:  Naoko Kobayashi; R James Barnard; Susanne M Henning; David Elashoff; Srinivasa T Reddy; Pinchas Cohen; Pak Leung; Jenny Hong-Gonzalez; Stephen J Freedland; Jonathan Said; Dorina Gui; Navindra P Seeram; Laura M Popoviciu; Dilprit Bagga; David Heber; John A Glaspy; William J Aronson
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

3.  GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects.

Authors:  Da Young Oh; Saswata Talukdar; Eun Ju Bae; Takeshi Imamura; Hidetaka Morinaga; WuQiang Fan; Pingping Li; Wendell J Lu; Steven M Watkins; Jerrold M Olefsky
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

4.  Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort.

Authors:  Song-Yi Park; Lynne R Wilkens; Susanne M Henning; Loïc Le Marchand; Kun Gao; Marc T Goodman; Suzanne P Murphy; Brian E Henderson; Laurence N Kolonel
Journal:  Cancer Causes Control       Date:  2008-09-27       Impact factor: 2.506

Review 5.  Multi-targeted therapy of cancer by omega-3 fatty acids.

Authors:  Isabelle M Berquin; Iris J Edwards; Yong Q Chen
Journal:  Cancer Lett       Date:  2008-05-13       Impact factor: 8.679

6.  A prospective study of intake of fish and marine fatty acids and prostate cancer.

Authors:  Katarina Augustsson; Dominique S Michaud; Eric B Rimm; Michael F Leitzmann; Meir J Stampfer; Walter C Willett; Edward Giovannucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-01       Impact factor: 4.254

7.  A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk.

Authors:  Jorge E Chavarro; Meir J Stampfer; Haojie Li; Hannia Campos; Tobias Kurth; Jing Ma
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06-21       Impact factor: 4.254

8.  Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer.

Authors:  Michael F Leitzmann; Meir J Stampfer; Dominique S Michaud; Katarina Augustsson; Graham C Colditz; Walter C Willett; Edward L Giovannucci
Journal:  Am J Clin Nutr       Date:  2004-07       Impact factor: 7.045

9.  Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids.

Authors:  Isabelle M Berquin; Younong Min; Ruping Wu; Jiansheng Wu; Donna Perry; J Mark Cline; Mike J Thomas; Todd Thornburg; George Kulik; Adrienne Smith; Iris J Edwards; Ralph D'Agostino; Hao Zhang; Hong Wu; Jing X Kang; Yong Q Chen
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

10.  Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study.

Authors:  A E Norrish; C M Skeaff; G L Arribas; S J Sharpe; R T Jackson
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  5 in total

1.  Effects of dietary omega-3 fatty acids on orthotopic prostate cancer progression, tumor associated macrophages, angiogenesis and T-cell activation-dependence on GPR120.

Authors:  Pei Liang; Susanne M Henning; Tristan Grogan; David Elashoff; Huihui Ye; Pinchas Cohen; William J Aronson
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-24       Impact factor: 5.455

2.  GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.

Authors:  Gabriele Carullo; Sarah Mazzotta; Margarita Vega-Holm; Fernando Iglesias-Guerra; José Manuel Vega-Pérez; Francesca Aiello; Antonella Brizzi
Journal:  J Med Chem       Date:  2021-04-10       Impact factor: 7.446

Review 3.  Pharmaceutical nanoformulation strategies to spatiotemporally manipulate oxidative stress for improving cancer therapies - exemplified by polyunsaturated fatty acids and other ROS-modulating agents.

Authors:  Rui Xue Zhang; Franky Fuh-Ching Liu; Hoyin Lip; Junhong Liu; Qianrong Zhang; Xiao Yu Wu
Journal:  Drug Deliv Transl Res       Date:  2022-01-22       Impact factor: 5.671

Review 4.  Associations among Dietary Omega-3 Polyunsaturated Fatty Acids, the Gut Microbiota, and Intestinal Immunity.

Authors:  Yawei Fu; Yadong Wang; Hu Gao; DongHua Li; RuiRui Jiang; Lingrui Ge; Chao Tong; Kang Xu
Journal:  Mediators Inflamm       Date:  2021-01-02       Impact factor: 4.711

5.  Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients.

Authors:  Hiroaki Takaya; Tadashi Namisaki; Mitsuteru Kitade; Naotaka Shimozato; Kosuke Kaji; Yuki Tsuji; Keisuke Nakanishi; Ryuichi Noguchi; Yukihisa Fujinaga; Yasuhiko Sawada; Soichiro Saikawa; Shinya Sato; Hideto Kawaratani; Kei Moriya; Takemi Akahane; Hitoshi Yoshiji
Journal:  World J Gastrointest Oncol       Date:  2019-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.